For the Culture By The Culture. ISSN: 3064-9331.
Portugal exported 66,305 kilograms of medical cannabis in the first half of 2026, yet domestic access still depends on strict prescriptions, limited indications, and unreimbursed preparations. Pot Culture Magazine examines INFARMED’s export data, patient-cost evidence, and the access gap inside one of Europe’s biggest medical cannabis supply hubs.
Canada surpassed California in June legal cannabis sales, exposing a California cannabis market weakened by local retail bans, limited licensed access, tax pressure, and an illicit economy the state still has not absorbed. Pot Culture Magazine examines the numbers behind the legal weed crown and why California’s cannabis problem is access, not demand.
Jamaica says ganja can be a Rastafari sacrament, but the right still runs into police discretion and state permission. Transport and approved land remain traps too. Pot Culture Magazine examines Jamaica’s July 2026 sacramental cannabis review, the Troy Harrison case, Zion Yard, and why religious freedom still gets treated like a compliance problem.
Thailand’s cannabis penalty rules expose the deeper failure behind the country’s 2022 decriminalization: an open retail market built without a durable adult-use law. Pot Culture Magazine examines prescription-only sales, controlled-herb enforcement, shop penalties, and how political whiplash turned Thailand’s cannabis boom into a legal access trap for sellers, patients, farmers, and licensed shops.
France keeps extending medical cannabis access while politically resisting broader legalization. Pot Culture Magazine examines the country’s cautious framework, frozen patient access, regulatory delays, and the growing contradiction between public rhetoric and the reality of cannabis reform already unfolding inside France.
The United Kingdom legalized medical cannabis in 2018, but most patients still cannot access it through the NHS. Private clinics filled the gap, creating a two-tier system where legal medicine exists, but access depends on money, specialist approval, narrow guidance, and a regulatory structure now facing sharper scrutiny.